Concepts (232)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fatigue | 15 | 2015 | 1239 | 1.830 |
Why?
|
| Neoplasms | 37 | 2022 | 15193 | 1.290 |
Why?
|
| Emergency Service, Hospital | 5 | 2018 | 1148 | 0.810 |
Why?
|
| Cancer Care Facilities | 3 | 2018 | 884 | 0.760 |
Why?
|
| Patient Handoff | 1 | 2018 | 39 | 0.630 |
Why?
|
| Hospitalists | 1 | 2018 | 57 | 0.600 |
Why?
|
| Venous Thromboembolism | 2 | 2023 | 335 | 0.580 |
Why?
|
| Central Nervous System Stimulants | 5 | 2009 | 225 | 0.570 |
Why?
|
| Thrombosis | 1 | 2022 | 781 | 0.540 |
Why?
|
| Neutropenia | 6 | 2008 | 968 | 0.540 |
Why?
|
| Fever | 6 | 2008 | 497 | 0.460 |
Why?
|
| Methylphenidate | 2 | 2003 | 103 | 0.430 |
Why?
|
| Venous Thrombosis | 4 | 2004 | 384 | 0.420 |
Why?
|
| Hypertension | 2 | 2016 | 1503 | 0.410 |
Why?
|
| Hospitalization | 4 | 2018 | 2083 | 0.400 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2010 | 234 | 0.350 |
Why?
|
| Anticoagulants | 5 | 2023 | 787 | 0.350 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2016 | 1533 | 0.340 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2010 | 259 | 0.340 |
Why?
|
| Ambulatory Care | 3 | 2008 | 554 | 0.340 |
Why?
|
| Antineoplastic Agents | 8 | 2016 | 14289 | 0.330 |
Why?
|
| Dyspnea | 3 | 2006 | 416 | 0.320 |
Why?
|
| Thromboembolism | 2 | 2012 | 155 | 0.320 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2009 | 89 | 0.310 |
Why?
|
| Palliative Care | 3 | 2010 | 2037 | 0.270 |
Why?
|
| Anti-Bacterial Agents | 6 | 2005 | 2992 | 0.270 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 2330 | 0.260 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2009 | 318 | 0.260 |
Why?
|
| Polymorphism, Genetic | 1 | 2010 | 1450 | 0.250 |
Why?
|
| Critical Pathways | 2 | 2008 | 149 | 0.250 |
Why?
|
| Patient Care Planning | 2 | 2003 | 297 | 0.240 |
Why?
|
| Pain Measurement | 1 | 2008 | 953 | 0.240 |
Why?
|
| Emergency Medical Services | 1 | 2008 | 429 | 0.230 |
Why?
|
| Chromosome Aberrations | 1 | 2010 | 1960 | 0.230 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 2195 | 0.220 |
Why?
|
| Aged, 80 and over | 15 | 2017 | 29902 | 0.220 |
Why?
|
| Humans | 50 | 2023 | 261506 | 0.210 |
Why?
|
| Aged | 24 | 2018 | 70117 | 0.210 |
Why?
|
| Patient Admission | 2 | 2018 | 220 | 0.210 |
Why?
|
| Middle Aged | 25 | 2018 | 86204 | 0.210 |
Why?
|
| Medical Oncology | 1 | 2010 | 1423 | 0.200 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2009 | 1209 | 0.200 |
Why?
|
| Risk Assessment | 4 | 2012 | 6869 | 0.190 |
Why?
|
| Adult | 24 | 2017 | 77950 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 7551 | 0.190 |
Why?
|
| Comorbidity | 6 | 2010 | 2352 | 0.180 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 4757 | 0.180 |
Why?
|
| Occupational Exposure | 2 | 2010 | 244 | 0.160 |
Why?
|
| Organizational Case Studies | 1 | 2018 | 42 | 0.160 |
Why?
|
| Treatment Outcome | 12 | 2015 | 32848 | 0.160 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2023 | 600 | 0.160 |
Why?
|
| Exercise Therapy | 3 | 2009 | 288 | 0.160 |
Why?
|
| Texas | 5 | 2010 | 6311 | 0.160 |
Why?
|
| Survivors | 2 | 2014 | 1031 | 0.160 |
Why?
|
| Male | 27 | 2017 | 123000 | 0.160 |
Why?
|
| Tetany | 1 | 1997 | 3 | 0.150 |
Why?
|
| Oncology Service, Hospital | 2 | 2010 | 48 | 0.150 |
Why?
|
| Medical Futility | 1 | 1997 | 54 | 0.150 |
Why?
|
| Female | 28 | 2017 | 141928 | 0.150 |
Why?
|
| Cathartics | 1 | 1997 | 42 | 0.150 |
Why?
|
| Outpatients | 2 | 1997 | 462 | 0.140 |
Why?
|
| Risk Factors | 10 | 2013 | 17523 | 0.140 |
Why?
|
| Phosphates | 1 | 1997 | 187 | 0.140 |
Why?
|
| Rural Health | 1 | 2016 | 51 | 0.140 |
Why?
|
| Fibrinolytic Agents | 2 | 2012 | 324 | 0.140 |
Why?
|
| Prevalence | 2 | 2017 | 3260 | 0.140 |
Why?
|
| Hyperglycemia | 2 | 2012 | 333 | 0.140 |
Why?
|
| Continuity of Patient Care | 1 | 2018 | 225 | 0.140 |
Why?
|
| Panax | 1 | 2015 | 33 | 0.130 |
Why?
|
| Antibiotic Prophylaxis | 1 | 1997 | 181 | 0.130 |
Why?
|
| Acute Disease | 3 | 2006 | 2422 | 0.130 |
Why?
|
| Retrospective Studies | 12 | 2023 | 37905 | 0.120 |
Why?
|
| Incidence | 3 | 2017 | 5673 | 0.120 |
Why?
|
| Terminal Care | 2 | 2007 | 447 | 0.120 |
Why?
|
| Inpatients | 2 | 2018 | 678 | 0.120 |
Why?
|
| Ethics, Medical | 1 | 1997 | 442 | 0.120 |
Why?
|
| Renal Insufficiency | 1 | 1997 | 321 | 0.120 |
Why?
|
| Antidepressive Agents | 2 | 2009 | 332 | 0.120 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 1993 | 36 | 0.110 |
Why?
|
| Plant Extracts | 1 | 2015 | 215 | 0.110 |
Why?
|
| Chronic Disease | 2 | 2014 | 1819 | 0.110 |
Why?
|
| Stomatitis | 1 | 2013 | 183 | 0.100 |
Why?
|
| Prospective Studies | 6 | 2017 | 12873 | 0.100 |
Why?
|
| Quality of Life | 6 | 2015 | 4532 | 0.090 |
Why?
|
| Administration, Oral | 3 | 2023 | 1544 | 0.090 |
Why?
|
| Health Resources | 3 | 2004 | 168 | 0.090 |
Why?
|
| Pyridones | 1 | 2012 | 348 | 0.090 |
Why?
|
| Polypharmacy | 1 | 2009 | 57 | 0.090 |
Why?
|
| Diarrhea | 1 | 2013 | 686 | 0.090 |
Why?
|
| Young Adult | 5 | 2012 | 21445 | 0.080 |
Why?
|
| Models, Theoretical | 2 | 2005 | 785 | 0.080 |
Why?
|
| Resuscitation Orders | 1 | 2009 | 68 | 0.080 |
Why?
|
| Advance Care Planning | 1 | 2009 | 86 | 0.080 |
Why?
|
| Pharmaceutical Preparations | 1 | 2009 | 152 | 0.080 |
Why?
|
| Survival Rate | 3 | 2009 | 12221 | 0.070 |
Why?
|
| Data Collection | 1 | 2009 | 620 | 0.070 |
Why?
|
| Social Support | 1 | 2009 | 560 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2014 | 4314 | 0.070 |
Why?
|
| Internal Medicine | 1 | 2007 | 124 | 0.070 |
Why?
|
| Insulin | 1 | 2012 | 1454 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2017 | 9244 | 0.070 |
Why?
|
| Time Factors | 5 | 2012 | 12926 | 0.060 |
Why?
|
| Vincristine | 2 | 2012 | 1511 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2012 | 2796 | 0.060 |
Why?
|
| Clavulanic Acid | 1 | 2004 | 9 | 0.060 |
Why?
|
| Health Services | 1 | 2005 | 105 | 0.060 |
Why?
|
| Health Personnel | 1 | 2010 | 625 | 0.060 |
Why?
|
| Constipation | 1 | 2006 | 177 | 0.060 |
Why?
|
| Clindamycin | 1 | 2004 | 50 | 0.060 |
Why?
|
| Ampicillin | 1 | 2004 | 58 | 0.060 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2009 | 598 | 0.060 |
Why?
|
| Virginiamycin | 1 | 2004 | 12 | 0.060 |
Why?
|
| Pilot Projects | 3 | 2012 | 2803 | 0.060 |
Why?
|
| Dalteparin | 1 | 2004 | 13 | 0.060 |
Why?
|
| Hemorrhage | 2 | 2023 | 712 | 0.060 |
Why?
|
| Vomiting | 1 | 2006 | 354 | 0.060 |
Why?
|
| Bacterial Infections | 2 | 2005 | 479 | 0.060 |
Why?
|
| Dexamethasone | 2 | 2012 | 1450 | 0.060 |
Why?
|
| Ciprofloxacin | 1 | 2004 | 89 | 0.060 |
Why?
|
| Enterococcus faecium | 1 | 2004 | 46 | 0.060 |
Why?
|
| Vancomycin Resistance | 1 | 2004 | 54 | 0.060 |
Why?
|
| Ceftazidime | 1 | 2004 | 57 | 0.060 |
Why?
|
| Adolescent | 5 | 2012 | 31252 | 0.060 |
Why?
|
| Health Services Research | 1 | 2005 | 233 | 0.060 |
Why?
|
| Self Administration | 1 | 2003 | 50 | 0.060 |
Why?
|
| Nausea | 1 | 2006 | 525 | 0.060 |
Why?
|
| Imipenem | 1 | 2003 | 23 | 0.060 |
Why?
|
| Oxazolidinones | 1 | 2004 | 60 | 0.060 |
Why?
|
| Physician-Patient Relations | 1 | 2009 | 792 | 0.060 |
Why?
|
| Rivaroxaban | 1 | 2023 | 59 | 0.060 |
Why?
|
| Pyrazoles | 1 | 2012 | 1471 | 0.060 |
Why?
|
| Acetamides | 1 | 2004 | 113 | 0.060 |
Why?
|
| Cephalosporins | 1 | 2003 | 148 | 0.050 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2004 | 157 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2003 | 2403 | 0.050 |
Why?
|
| Patient Education as Topic | 2 | 2007 | 748 | 0.050 |
Why?
|
| Cyclophosphamide | 2 | 2012 | 3001 | 0.050 |
Why?
|
| Doxorubicin | 2 | 2012 | 3005 | 0.050 |
Why?
|
| Decision Trees | 1 | 2002 | 178 | 0.050 |
Why?
|
| Heparin | 1 | 2004 | 360 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2007 | 899 | 0.050 |
Why?
|
| Cost of Illness | 1 | 2004 | 498 | 0.050 |
Why?
|
| Disease Progression | 2 | 2006 | 6682 | 0.050 |
Why?
|
| Sleep | 1 | 2003 | 413 | 0.040 |
Why?
|
| Clinical Trials as Topic | 2 | 2003 | 3719 | 0.040 |
Why?
|
| Research | 1 | 2002 | 415 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2005 | 1467 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2002 | 552 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2004 | 2315 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2007 | 1054 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 5687 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 2013 | 3976 | 0.040 |
Why?
|
| Cost Control | 1 | 1997 | 48 | 0.040 |
Why?
|
| Pain | 1 | 2006 | 1658 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2006 | 4988 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 4892 | 0.040 |
Why?
|
| Hypocalcemia | 1 | 1997 | 59 | 0.040 |
Why?
|
| Magnesium | 1 | 1997 | 160 | 0.040 |
Why?
|
| Anemia | 1 | 2002 | 689 | 0.040 |
Why?
|
| Managed Care Programs | 1 | 1996 | 74 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2012 | 15862 | 0.040 |
Why?
|
| Disease Management | 2 | 2015 | 1052 | 0.040 |
Why?
|
| Counseling | 2 | 2010 | 381 | 0.030 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1996 | 137 | 0.030 |
Why?
|
| Narcotics | 1 | 1996 | 123 | 0.030 |
Why?
|
| Terminally Ill | 1 | 1996 | 91 | 0.030 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 1996 | 119 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2015 | 4938 | 0.030 |
Why?
|
| Algorithms | 2 | 2007 | 3890 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 1997 | 829 | 0.030 |
Why?
|
| Diet | 1 | 2003 | 1440 | 0.030 |
Why?
|
| Exercise | 1 | 2002 | 1183 | 0.030 |
Why?
|
| Length of Stay | 2 | 2004 | 1900 | 0.030 |
Why?
|
| Standard of Care | 1 | 2015 | 243 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 1997 | 1382 | 0.030 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2014 | 60 | 0.030 |
Why?
|
| Mass Screening | 1 | 2002 | 1509 | 0.030 |
Why?
|
| United States | 4 | 2014 | 15433 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2000 | 4298 | 0.030 |
Why?
|
| Insulin, Long-Acting | 1 | 2012 | 18 | 0.030 |
Why?
|
| Insulin Glargine | 1 | 2012 | 20 | 0.030 |
Why?
|
| Age Factors | 2 | 2014 | 5377 | 0.030 |
Why?
|
| Factor Xa | 1 | 2012 | 26 | 0.030 |
Why?
|
| C-Peptide | 1 | 2012 | 107 | 0.030 |
Why?
|
| Factor Xa Inhibitors | 1 | 2012 | 70 | 0.030 |
Why?
|
| Thiazolidinediones | 1 | 2012 | 148 | 0.020 |
Why?
|
| Canada | 1 | 2012 | 429 | 0.020 |
Why?
|
| Electrocardiography | 1 | 1997 | 1145 | 0.020 |
Why?
|
| Health Status | 1 | 2014 | 590 | 0.020 |
Why?
|
| Occupational Health | 1 | 2010 | 95 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2000 | 4320 | 0.020 |
Why?
|
| Burkitt Lymphoma | 1 | 2012 | 335 | 0.020 |
Why?
|
| Decision Making | 1 | 1997 | 1287 | 0.020 |
Why?
|
| Prognosis | 2 | 2012 | 21713 | 0.020 |
Why?
|
| Lung Neoplasms | 3 | 1997 | 11538 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2000 | 9180 | 0.020 |
Why?
|
| Physical Examination | 1 | 2010 | 299 | 0.020 |
Why?
|
| Metformin | 1 | 2012 | 378 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 586 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2012 | 1244 | 0.020 |
Why?
|
| Carnitine | 1 | 2007 | 94 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2010 | 672 | 0.020 |
Why?
|
| Nutrition Assessment | 1 | 2007 | 169 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2012 | 2588 | 0.020 |
Why?
|
| Concept Formation | 1 | 2005 | 32 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 10035 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 2594 | 0.020 |
Why?
|
| Lymphoma | 1 | 1993 | 1467 | 0.020 |
Why?
|
| Linezolid | 1 | 2004 | 64 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2014 | 6100 | 0.010 |
Why?
|
| Amikacin | 1 | 2003 | 34 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2007 | 1546 | 0.010 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2004 | 66 | 0.010 |
Why?
|
| Dietary Supplements | 1 | 2007 | 558 | 0.010 |
Why?
|
| Hospital Costs | 1 | 2004 | 228 | 0.010 |
Why?
|
| Forecasting | 1 | 2005 | 694 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2008 | 674 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 5112 | 0.010 |
Why?
|
| Vancomycin | 1 | 2003 | 273 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2004 | 994 | 0.010 |
Why?
|
| Methotrexate | 1 | 2004 | 999 | 0.010 |
Why?
|
| Biomarkers | 1 | 2012 | 5047 | 0.010 |
Why?
|
| Catheterization, Central Venous | 1 | 2003 | 354 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 10001 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2004 | 945 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 1997 | 7789 | 0.010 |
Why?
|
| Animals | 1 | 2003 | 59536 | 0.010 |
Why?
|
| Cytarabine | 1 | 2004 | 1973 | 0.010 |
Why?
|
| Remission Induction | 1 | 2004 | 3569 | 0.010 |
Why?
|
| Logistic Models | 1 | 2004 | 3441 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 1996 | 15694 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2004 | 14889 | 0.010 |
Why?
|